ReviewCurrent opinion in investigational drugs (London, England : 2000)2010

NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

Amani D Politano et al.PubMed ↗Full text ↗

No numbers read from the abstract.